objective Diabetes mellitus is a common endocrinopathy in patients with b-thalassaemia major (b-TM), which is high prevalent in southern China. This study aimed to determine the cause and prevalence of glycaemic disorders in Chinese children with b-TM.
Introduction
Beta-thalassaemia (b-TM) is the most common chronic haemolytic anaemia in southern China with a high incidence in Guangdong and Guangxi [1, 2] . Patients with b-TM need lifelong blood transfusion leading to iron overload [3] . Although survival has improved in the western countries [4] , patients in this province are treated poorly and the age of survival is still under 12 years [1] . Chronic iron overload results in cardiac and hepatic dysfunction as well as multiple endocrine abnormalities [4, 5] .
Diabetes is an important problem as the severity and type of glucose abnormalities vary greatly in different studies [6] [7] [8] [9] . In addition, controversy about the natural history of diabetes in thalassaemia major still exists [10] . Although insulin deficiency secondary to pancreatic islet iron deposition is the principal cause of the abnormalities of glucose metabolism observed in b-TM [7, 11] , a key role of insulin resistance in the mediation of these metabolic abnormalities has been reported [7, 9, 12, 13] . Factors such as pancreatic autoimmunity, liver function abnormalities, heredity and family history may all be involved [8, [13] [14] [15] [16] . Recent studies using imaging such as cardiac T2* have suggested that iron overload in the heart is associated with endocrine complications [17, 18] . However, comparisons of cardiac T2*values and glucose metabolism disorders in young thalassaemia patients are scarce.
The present study was designed to evaluate glucose homeostasis in Chinese children with b-TM under the age of 18 years. We also aimed to determine the relationship between glycaemic markers and the iron overload markers such as cardiac T2* and the type of chelation therapy.
Patients and methods
In this prospective, case-controlled, observational study, we enrolled 267 children with b-TM and 80 healthy agematched controls between January 2010 and January 2014. The healthy volunteer controls were recruited from local primary and middle schools.
All children with b-TM were recruited from the red cell unit of First Affiliated Hospital of Guangxi Medical University, China. All b-TM children received blood transfusion and were chelated either by monotherapy (desferrioxamine, deferasirox, deferiprone) or a combination therapy according to their body weight, degree of iron overload and tolerance. 80 healthy non-thalassaemic children also were recruited from the same hospital. The study was ethically approved by the Medical ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All subjects' parents of minors gave written consent before participating in the study.
Heights and weights were measured by the same observer. Body mass index (BMI) was then calculated using the formula (BMI = body weight (kg)/height (m 2 ). Height of less than the 3rd percentile or 2 SD below the average height of normal people of the same age and sex was defined as short stature. Weight of less than 2 SD of the average height of normal people of the same age and sex was defined as underweight. BMI < 18.5 kg/m² was considered as underweight.
Data of patients with thalassaemia major were retrieved from hospital records. Patients received blood transfusions every 2-4 weeks to maintain their haemoglobin levels at >10 g/dl. Patients also received iron chelation therapy when their serum ferritin levels were >1000 lg/l or if they received more than 12 units of blood transfusion. Patients received deferasirox (10-40 mg/kg/day) or deferiprone monotherapy (75-90 mg/kg/day; three times a day, or deferoxamine and deferiprone (deferoxamine 50 mg/kg/ day for 3 days every 2 weeks 75-90 mg/kg/day as three times a day) as combination therapy.
Haematological data including markers of iron overload were collected from the case records. These included total amount of units of blood received, type of chelation therapy, pre-transfusion haemoglobin, co-morbidities, serum ferritin and liver function test. A serum ferritin value of >2500 lg/l was considered as an indicator of severe iron overload. All MRI examinations were performed using a 1.5-T scanner (Sonata, Siemens Medical, Erlangen, Germany) with CMR tools (Cardiovascular Imaging Solutions, London, UK). We assessed cardiac T2*; however, we did not assess the hepatic and pancreas T2* because these values were not always measured during examination as children were too young to cooperate or claustrophobic. We collected the cardiac T2* values from 157 patients.
We measured fasting glucose and insulin levels in both b TM and control children by collecting blood samples in the early morning (0800-0900 h) after an overnight fast of at least 8 h. All samples were centrifuged at 3000 g for 10 min at room temperature and stored at À80°C for batch assay. Fasting blood glucose (FPG) and serum insulin (FINS) were measured by glucose oxidase method (7600 Hitachi automatic biochemical Analyser) and using commercially available Radioimmunoassay Kit (Beijing North Institute of Biological Technology, China). Diagnoses of diabetes mellitus and glucose intolerance were made using criteria of American Diabetes Association [8, 19] . Impaired fasting glucose (IFG) was defined as fasting serum glucose of >5.6-7.0 mmol/l and normal fasting glucose was defined as a glucose level of <100 mg/dl. Diabetes was diagnosed if the fasting serum glucose was >7.0 mmol/l on at least two occasions. We evaluated the HOMA indices for beta-cell function, which was widely validated clinically and epidemiologically [20, 21] . The HOMA-IR index, the HOMA of insulin resistance was the product of basal glucose (mmol/l) and insulin (lU/ml) levels divided by 22.5; normal level was 0.8-1.6. The diagnosis of insulin resistance was made when HOMA-IR value was >5. The HOMA-B index was computed as the product of 20 and basal insulin levels divided by the value of basal glucose concentrations minus 3.5; the normal value was 130-400. This was proposed to be a good measure of b cell function [8] . The quantitative insulin sensitivity check index (QUIKI) correlated well with glucose clamp studies (r = 0.78), and was useful for measuring the insulin sensitivity index (ISI), which was the inverse of insulin resistance (IR) [8] .
Statistical analysis
Data were presented as mean AE standard error of mean (SEM) or median (range) for continuous variables. Mann-Whitney U test or t test were used for comparison of continuous variables between the groups. Student t test was used for comparison of data between groups. Pearson correlation was used to test the relationship between markers of iron overload and other variables. To control for confounding variables, stepwise logistic regression analysis was used to calculate odds ratio (ORs) with 95% confidence interval (CI) for every factor in isolation and for construction of multivariate models. Statistical significance was set at P < 0.05.
Results

Patient characteristics
On average, b-TM children were older than the controls (7.9 AE 0.2 vs. 10.3 AE 0.3 years; P < 0.001, Table 1 ). This difference was due to the fact that there were 55 under-fives children in the b-TM group vs. 1 in the control group. In the b-TM group, there were 171 (60%) males and 96 (40%) females, which was similar to the controls (M = 65% and F = 35%). All b-TM cases were transfusion-dependent and had a pre-transfusion Hb of 97.5 AE 1.2 g/l. Majority of the children had suboptimal chelation therapy; 115 (43%) were on deferiprone either as monotherapy or as combination therapy (with DFO or deferasirox). 90 children (34%) were not on any type of chelation therapy (9%) or were taking chelation very irregularly (24%). Heights (P < 0.01), weights (P < 0.01) and BMI (P < 0.001) of b-TM cases were significantly lower than those of controls. 93 (35%) b-TM children had short stature with 92% (246) having low BMI (<18.5 kg/sqm 2 ), whereas none in the control group did.
Glucose metabolism
In the b-TM group, the mean fasting glucose levels (5.2 AE 0.11 mmol/l vs. 4.5 AE 0.04 mmol/l; P < 0.001) and fasting insulin levels (5.5 AE 0.65 vs. 3.5 AE 0.3 mU/l; P < 0.01) were higher than those to the controls (Table 1 ). In the b-TM group, 81 (30%) had IFG and five (2%) had diabetes. The youngest patients with IFG and diabetes were 3 and 13 years old respectively. In contrast, in the control group, none had IFG or diabetes (Table 1) . Similarly, fasting insulin (P < 0.001), HOMA-IR (P < 0.01) and HOMA-B (P < 0.01) were significantly higher in b-TM cases than the control group. Of 27 b-TM children with insulin resistance, seven (26%) had normal glucose metabolism.
b-TM with or without impaired fasting glucose. For further analysis, the data of children with IFG and diabetes were pooled as the sample size of children with diabetes was small. As Table 2 shows, height, weight and BMI were significantly lower in b-TM cases with IFG than in those with normal fasting glucose levels ( Table 2) . Figure 1 compared the glucose homeostasis parameters in b-TM with or without IFG. b-TM children with IFG were significantly older (10 AE 0.4 years vs. 7 AE 0.2 years; P < 0.001) and had higher fasting insulin (7.5 AE 0.8 vs. 4.6 AE 0.3 mU/l; P < 0.001), HOMA-IR (2.1 AE 0.3 vs. 1.0 AE 0.1; P < 0.001) and HOMA-B (20.4 AE 2.4 vs. 15.8 AE 0.1; P < 0.05) than those with normal fasting glucose levels. ISI was significantly lower in b-TM children with IFG than those without (0.8 AE 0.1 vs. 1.6 AE 0.1; P < 0.001) (Figure 1 ).
There was a significant correlation between fasting glucose levels, age (y = À0.85 + 1.68x; r = 0.40; P < 0.001), insulin (y = À4.06 + 1.83x; r = 0.30; P < 0.01), HOMA IR levels (y = À2.5 + 0.74x; r = 0.41; P < 0.01), serum ferritin (y = À474.1 + 944.77x; r = 0.32; P < 0.01) and ISI (y = 4.16 À0.54x; r = À0.48; P < 0.001 (Figure 2 ).
Markers of glucose homeostasis and iron overload. The markers of iron overload such as total units of blood transfused (P < 0.01), serum SF levels (P < 0.001) and ALT (P < 0.05) were significantly higher in children with IFGthan those without. Children with serum ferritin levels of >2500 had a higher prevalence of IFG than those with serum ferritin levels of<2500 ng/ml (40% vs. 2.1%; P < 0.001). The mean cardiac T2* of children with IFG was significantly lower than that of the non-IFG group (22.0 + 1.65 ms vs. 28.9 AE 1.3 ms; P < 0.01). 51% of children with IFG had T2*of <20 ms vs. 24% who had normal glucose levels (P < 0.01) ( Table 2) .
Risk factors for abnormal glucose metabolism in b-TM. Stepwise logistic regression analysis was carried out on variables that were significant at the 5% level or less in the multivariate model. This showed that age of >10 years (OR 2.9; 95% CI 1.13 to 6.83; P < 0.05), ferritin level of >2500 lg/l (OR 5.3; 95% CI 2.3-12.3; P < 0.01), cardiac T2* of <20 ms (OR 8.8; 95% CI 3.5 to 10.3; P < 0.01) and serum ALT of >50 IU/l (OR 2.1; 95% CI 1.20 to 3.7; P < 0.01) had independent effects on the abnormal glucose metabolism in the b-TM subjects ( Table 2) . As regards the type of chelation therapy, children on deferiprone-containing regimes (monotherapy or combination therapy) had a significant protective effect on IFG (OR 0.4; 95% CI 0.23-0.81; P < 0.05). Factors such as haemoglobin of <10 g/dl or alkaline phosphatase had no significant effect on the IFG status of the b-TM patients (Table 3) . 
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Discussion
This study found that the overall prevalence of diabetes and IFG in thalassaemic children under 18 years is 2% and 30%, respectively. This was significantly higher in cases than controls and the background population of Chinese children, where the prevalence of type 1 and type 2 diabetes is 0.09 and 0.08%, respectively [20] . Literature on the incidence and severity of glucose metabolism abnormalities appears to be largely restricted to adults. The reported incidence of impaired fasting glucose ranges from 6.5% to 27% [8, 19] , whereas that of diabetes was between 0 and 26% [8, 19] . A multicentric Italian study involving 1861 thalasasemia patients in 1995 showed that the overall incidence of glycaemic abnormalities was 4.9% [21] . More recently, in the UK, Ang et al. [22] showed a high incidence of glycaemic abnormalities of 41% in well-managed adult thalassaemic patients [22] . However, little is known about glycometabolic abnormalities in thalassaemia children as young as 2-3 years of age. The prevalence of glucose metabolism dysregulation found in our study was much higher than 13%, which was reported by Metwalley et al. (2014) involving 60 thalassaemic children [23] . This wide variation in prevalence was multifactorial: dependent on the duration of blood transfusion, degree of iron load, organ dysfunction, type of chelators, compliance to therapy and age of patient. The exact reason for this early occurrence of glycaemic abnormalities in children of the index population remains unclear. But it might be due to the following factors: b-TM cases of Guanxi district of Mainland China may not be representative of children in western countries who were optimally treated from an early age with transfusion and chelation therapy. It is noteworthy that most children in this cohort, despite being on a transfusion programme from a very early age, were poorly transfused and suboptimally chelated due to chronic shortage of blood and scarce resources within the health insurance. This contributes to an increased iron burden with 80% childhood mortality in Guanxi [24] , which might be a major contributing factor for the high prevalence of diabetes in this cohort. Our finding suggests that SF of >2500 ng/ml and cardiac T2* of <20 ms are independent risk factors for development of IFG supports the iron burden hypothesis. In this study, children over 10 years of age had a threefold higher risk of development of IFG/diabetes, with fasting glucose, fasting insulin and HOMA-IR being positively correlated with age. HOMA-IR, the gold standard marker of insulin resistance, showed a significant positive correlation with age, serum ferritin and ALT levels suggesting that degree of iron overload and hepatic dysfunction were responsible for the insulin resistance. This finding was concordant with other studies, which demonstrated increased insulin levels with resistance in thalassaemic patients with IFG [7] . Controversy still exists regarding the aetiology of glycaemic abnormalities in adolescent and adult thalassaemics. Insulin deficiency and/or resistance have been reported by different studies in such group [13, 15, 16] . As our patients were very young, and probably represented an early stage of glycometabolic abnormality in the natural history of haemosiderosis, they had insulin resistance rather than deficiency. We propose that unless the iron burden is corrected with intensive chelation, eventually irreversible damage to b-cell function is likely to ensue in this cohort with the development of insulin-dependent overt diabetes.
Although we do not have data on hepatic iron, liver enzyme data suggested that children with ALT levels of >50 IU/l are at twofold higher risk of development of IFG. Although we did not measure hepatic iron in this study, the value of liver iron over cardiac T2* as a predictive risk factor for development of endocrinopathies was small [25] . Perhaps this is attributable to the fact that cardiac iron stores were emptied slower than liver iron stores after chelation therapy.
Insulin resistance probably occurred at the level of the liver (due to hepatic load), where it might interfere with the insulin's ability to suppress hepatic glucose uptake, and also at the level of the muscle, where iron deposits might decrease the glucose uptake [21] . We failed to find any correlation between ALT and glycaemic markers. Furthermore, in the absence of hepatic iron data it was impossible to pinpoint hepatic iron load as the key contributor of insulin resistance. As this was a cross-sectional study, we could not address the natural history of hepatic siderosis and determine its relationship with glycaemic and hepatic load markers. This could be addressed in another study.
It is well established that Cardiac T2* is a better marker of iron load than serum ferritin [17, [25] [26] [27] [28] [29] . Recently Ang et al. [22] showed that cardiac T2* could be used as a surrogate marker of pancreatic siderosis. Although we have no data on pancreatic iron, we found that cardiac T2* of <20 ms was an independent risk factor for development of IFG/diabetes. Children who had cardiac T2* of <20 ms approximately had a ninefold higher risk of development of abnormal glucose metabolism secondary to iron induced pancreatic damage. Studies in Hong Kong and China showed the usefulness of cardiac T2* as a marker of cardiac siderosis and also compared cardiac iron load with pancreatic siderosis. In a large study of 180 patients in Hong Kong [25] investigators showed that pancreatic and cardiac load were strongly correlated.
Furthermore a recent study in Taiwan [7] also showed that thalassaemic patients with diabetes were significantly older, had higher ferritin levels, had smaller pancreas volume, abnormal glycaemic parameters and lower cardiac T2* than patients without diabetes.
In our study, other factors such as poor nutrition, anaemia and irregular chelation therapy might have also contributed to the high prevalence of IFG. Our children were poorly chelated and had different types and doses chelation therapy (monotherapy, or as combination therapy) at various times. Therefore, it was not possible to dissect the relationship and draw meaningful conclusions between individual chelators on haemosiderosis including pancreatic function or IFG.
Despite these limitations, our data suggested that those children who were on deferiprone-based therapy (mono or combination) had a significantly reduced risk of developing IFG. This finding is novel and very encouraging, as other investigators have also shown that reversal or correction of abnormal glycaemia was feasible in adults using higher doses of DFP-based therapy [17, [28] [29] [30] [31] . Our study is the first to suggest that a Deferiprone-based regime could actually prevent the risk of IFG in children. However, further studies are required to prove this proposition.
MR imaging could be used to effectively detect and accurately quantify excess iron deposition in pancreas [17] . But little is known regarding the relationship between cardiac T2* and glucose metabolism disorders in b-TM Chinese patients. But Ang et al. [22. ] reported myocardial iron loading as a strong risk factor for the onset of diabetes in adults withb-TM. Au [17] had confirmed this view in a cross-sectional study of 180 patients with b-TM.
We did not undertake pancreatic imaging to assess iron load as it was expensive and was not validated in our group of patients. Estimation of pancreatic iron could be an option to consider in future studies. But one must appreciate that organ dysfunction is dependant on reserve and secretory capacity and therefore the presence of iron does not necessarily indicate a cause-and-effect relationship. Moreover, pancreatic T2 * values had a greater variability than liver or cardiac T2 *values [18, 22, 28, 31] and relationship between pancreatic T2 * and age or ferritin levels was often inconclusive.Furthermore, degree of pancreatic iron overload assessed by MRI did not invariably correlate with the severity of diabetes or impaired glucose tolerance [25] . However, in some studies the iron dynamics of pancreas were similar to those of the heart, and cardiac T2 * values were closely related to pancreatic T2* [17, 28, 31] .
As impaired fasting glucose was also associated with abnormal cardiac T2* we suspect that there might be some value in comparing cardiac MRI with fasting blood sugar/insulin for prediction of glycaemic metabolic disorders. The main advantage of such test is in predicting high risk patients before irreversible damage occurred, allowing time for intervention with chelation and other therapies [8] .
One of the limitations of this study is its cross-sectional nature which did not allow us to evaluate the age related changes and progression or the natural history of glycaemic abnormalities. Another limitation was the absence of hepatic iron data. Traditionally, the quantification of iron overload was undertaken indirectly from serum ferritin levels and directly from liver biopsy. However, we did not undertake liver biopsy, as it was an invasive procedure. We acknowledge that ferritin measurements were poorly correlated with organ iron stores, especially with those of the heart [27] .
Perhaps a 1-stop technique using an MRI of heart, liver, pancreas and pituitary could be applied in future for a better understanding of pathophysiology. If such a longitudinal study was performed from an early age it would likely cast light on the natural history of the glycometabolic disorders, cardiac siderosis and other endocrinopathies of the anterior pituitary gland. This would be important to properly understand the pathophysiology of glycaemic disorders and iron load, and to advocate prompt and better care.
Conclusion
Our data suggest that children with b-TM have a higher incidence of glycaemic disorders, perhaps due to insulin resistance secondary to increased iron burden. Deferipronecontaining chelation therapy may have protective effect.
